These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16157956)

  • 1. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.
    Ando J; Kakishita M; Sakai K; Komura Y; Nishiyama K; Iwabuchi M; Yokoi H; Yasumoto H; Nosaka H; Nobuyoshi M
    Int Heart J; 2005 Jul; 46(4):647-56. PubMed ID: 16157956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].
    Amino M; Yoshioka K; Iwata O; Fujikura H; Deguchi Y; Ban K; Shiina Y; Goto S; Handa S; Tanabe T; Nakagawa Y; Morita S; Iwase H; Yamamoto I; Inokuchi S; Marutani Y
    J Cardiol; 2003 Mar; 41(3):127-34. PubMed ID: 12674997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia.
    Shiga T; Tanaka K; Kato R; Amino M; Matsudo Y; Honda T; Sagara K; Takahashi A; Katoh T; Urashima M; Ogawa S; Takano T; Kasanuki H;
    Resuscitation; 2010 Jan; 81(1):47-52. PubMed ID: 19913983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation.
    Katoh T; Mitamura H; Matsuda N; Takano T; Ogawa S; Kasanuki H
    Circ J; 2005 Oct; 69(10):1237-43. PubMed ID: 16195624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nifekalant hydrochloride as an effective treatment for postoperative ischemic heart disease].
    Enomoto Y; Aoki K; Toshimitsu Y; Inai Y; Asakura T; Furuta S
    Kyobu Geka; 2005 Apr; 58(4):316-9. PubMed ID: 15828253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia.
    Igawa M; Aonuma K; Okamoto Y; Hiroe M; Hiraoka M; Isobe M
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):735-42. PubMed ID: 12409982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function].
    Murakami T; Makino Y; Kato H
    Kyobu Geka; 2007 Jun; 60(6):469-73. PubMed ID: 17564063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.
    Yusu S; Ikeda T; Mera H; Miyakoshi M; Miwa Y; Abe A; Tsukada T; Ishiguro H; Shimizu H; Yoshino H
    Circ J; 2009 Nov; 73(11):2021-8. PubMed ID: 19724153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment for perioperative arrhythmias with nifekalant hydrochloride].
    Nishida M; Okada H; Murakami M; Hamano K
    Kyobu Geka; 2006 Mar; 59(3):210-3. PubMed ID: 16528993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation.
    Tahara Y; Kimura K; Kosuge M; Ebina T; Sumita S; Hibi K; Toyama H; Kosuge T; Moriwaki Y; Suzuki N; Sugiyama M; Umemura S
    Circ J; 2006 Apr; 70(4):442-6. PubMed ID: 16565562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm.
    Nagao K
    Circ J; 2010 Nov; 74(11):2285-7. PubMed ID: 20962421
    [No Abstract]   [Full Text] [Related]  

  • 12. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation.
    Kokaji K; Okamoto M; Hotoda K; Kumamaru H
    Jpn Heart J; 2004 Jul; 45(4):691-5. PubMed ID: 15353881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest.
    Tagami T; Matsui H; Ishinokami S; Oyanagi M; Kitahashi A; Fukuda R; Unemoto K; Fushimi K; Yasunaga H
    Resuscitation; 2016 Dec; 109():127-132. PubMed ID: 27568110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy for ventricular tachyarrhythmia in heart failure.
    Shiga T; Kasanuki H
    Circ J; 2007; 71 Suppl A():A90-6. PubMed ID: 17587746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
    Ohashi J; Yasuda S; Miyazaki S; Shimizu W; Morii I; Kurita T; Kawamura A; Kamakura S; Nonogi H
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):274-9. PubMed ID: 17204905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation.
    Wang J; Hua W; Zhu J; Yang YM; Wang FZ; Pu JL; Chen KP; Zhang S
    Chin Med J (Engl); 2010 Aug; 123(15):2028-33. PubMed ID: 20819537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride.
    Yasuda S; Sawano H; Hazui H; Ukai I; Yokoyama H; Ohashi J; Sase K; Kada A; Nonogi H;
    Circ J; 2010 Nov; 74(11):2308-13. PubMed ID: 20877128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach.
    Sahara M; Sagara K; Yamashita T; Iinuma H; Fu LT; Watanabe H
    Circ J; 2003 Aug; 67(8):712-4. PubMed ID: 12890916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.